Oxigene Inc. (OXGN:NASDAQ)
Snapshot of Oxigene Inc. (OXGN)
|
OPEN
$1.32
|
PREVIOUS CLOSE
$1.25
|
|
|
DAY HIGH
$1.32
|
DAY LOW
$1.16
|
|
|
52 WEEK HIGH
05/22/09 - $2.78
|
52 WEEK LOW
03/5/09 - $0.52
|
|
|
MARKET CAP
78.7M
|
AVERAGE VOLUME 3 mo
529.4K
|
|
|
DILUTED EPS TTM
$-0.58
|
SHARES OUTSTANDING
62.5M
|
|
|
OXGN Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
OXGN Details
OXiGENE, Inc., a biopharmaceutical company, develops small-molecule therapeutics to treat cancer and eye diseases in the United States. It focuses on the development and commercialization of drug candidates that disrupt abnormal blood vessels associated with solid tumor progression and visual impairment in ocular diseases. The company’s product ZYBRESTAT, which is in Phase II/III pivotal registration study as a potential treatment for anaplastic thyroid cancer, as well as in Phase II clinical trials for other solid tumors, including non-small cell lung cancer and platinum resistant ovarian cancer. It also develops a topical formulation of ZYBRESTAT for ophthalmological diseases and conditions, such as age-related macular degeneration. In addition, OXiGENE develops OXi4503, which is in Phase I clinical trial for solid tumors. It has a strategic collaboration agreement with Symphony Capital Partners, L.P. to support the advancement of ZYBRESTAT for oncology and ophthalmology. The company was founded in 1988 and is headquartered in Waltham, Massachusetts.
OXGN Top Compensated Officers
Key developments for Oxigene Inc. (OXGN)
Oxigene Inc. announced that they will report Q3, 2009 results on November 09, 2009.
Oxigene Inc., Q3 2009 Earnings Call, Nov-09-2009
To discuss the VaxGen merger transaction and provide a corporate update
Stock Quotes
| Recently Viewed | |||
| OXGN | $1.26 USD | +0.01 |  |
|---|---|---|---|
| DRIV | $26.44 USD | +0.40 |  |
| HURC | $15.38 USD | +0.44 |  |
| CVGI | $5.35 USD | +0.08 |  |
| ENDP | $22.75 USD | +0.55 |  |
Market data is delayed at least 20 minutes.
OXGN Competitors
| Company | Last | Change |
| Cell Therapeutics Inc | $1.12 USD | +0.04 |
| Curis Inc | $2.70 USD | +0.44 |
| EntreMed Inc | $1.11 USD | +0.08 |
| Insite Visions | $0.37 USD | -0.02 |
| Vion Pharmaceuticals Inc | $0.75 USD | +0.14 |
| View Industry Companies | ||
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | OXGN | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | NM | Not Meaningful |
| Price/Book | 6.1x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | NM | Not Meaningful |
|
OXGN |
||
OXGN transactions
| Type Date |
Target |
|
Merger/Acquisition
October 14, 2009 |
VaxGen Inc. |
|
Private Placement
July 15, 2009 |
-- |
|
Merger/Acquisition
July 2, 2009 |
Symphony ViDA, Inc. |
Companies Toolbox
Update/report
Submit private company
Upload your company video
Newsletter
Blogs
RSS feeds
Podcasts
VideosSEARCH FOR JOBS
Post a Job- Painesville, OH-Avery Dennison
- Houston, TX-Halliburton
- Houston, TX-Halliburton
- New York, NY-Duff & Phelps
Jobs by SimplyHired
Recommend A Data Enhancement Or Correction
For Oxigene Inc. (OXGN) Snapshot
Submitting this data update / error report instantly puts the correct information in the hands of our researcher, who will investigate your report and, if necessary, make the changes to the company profile. Be sure to fill out the form completely.
Please indicate in which section the error appears. Section headers are in light gray type at the top of each CIC page module.
Please indicate which data is in error.
Please provide your name and email address in case our researchers need to get in touch with you as they investigate the error.
Describe why you feel the data point is incorrect and indicate sources our researchers should check when they investigate the error.
